WASHINGTON — Of all his campaign promises, President Trump’s vow to bring down drug prices was perhaps the most popular.

An assortment of interest groups spoke out loudly and passionately on the need for action, from hospitals to doctors to insurers to generic drug makers to patients themselves.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Anonymous say: “pharma does stock buybacks just like other companies- what’s wrong with that”. I’ll tell you what’s wrong. Other companies ‘ customers don’t rely on them as a matter of life and death. Pharma companies should not be operating like hedge funds which is exactly how they now operate. As far as funding research you’ve got it totally backwards. The NIH is in the business of funding the riskiest research. You should read up on how all these wonderful drugs you think were dreamed up by pharma had their origins in NIH (taxpayer funded) research. I mentioned Sovaldi earlier as just one example. The new carT therapies are another example. Fundamental research in this country is still funded mostly by the NIH but Republicans may succeed in gutting that too before they’re through.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy